Total Payments
$3,618
2024 Payments
$1,361
Companies
51
Transactions
152
Medicare Patients
7,779
Medicare Billing
$4.1M
Payment Breakdown by Category
Food & Beverage$2,916 (80.6%)
Consulting$400.00 (11.1%)
Education$302.44 (8.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,916 | 140 | 80.6% |
| Consulting Fee | $400.00 | 1 | 11.1% |
| Education | $302.44 | 11 | 8.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $414.39 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $322.77 | 14 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $247.87 | 13 | $0 (2024) |
| Merck Sharp & Dohme LLC | $199.09 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $180.41 | 8 | $0 (2024) |
| Astellas Pharma US Inc | $178.87 | 3 | $0 (2024) |
| Genentech USA, Inc. | $157.74 | 7 | $0 (2024) |
| PFIZER INC. | $150.15 | 7 | $0 (2024) |
| Janssen Biotech, Inc. | $115.63 | 6 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $99.42 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,361 | 56 | Astellas Pharma US Inc ($159.94) |
| 2023 | $1,024 | 48 | Merck Sharp & Dohme LLC ($115.36) |
| 2022 | $585.27 | 29 | Genentech USA, Inc. ($87.19) |
| 2021 | $24.89 | 2 | Janssen Biotech, Inc. ($12.97) |
| 2020 | $417.17 | 2 | Daiichi Sankyo Inc. ($400.00) |
| 2019 | $49.43 | 3 | Lilly USA, LLC ($18.73) |
| 2018 | $87.40 | 7 | Seattle Genetics, Inc. ($36.87) |
| 2017 | $69.02 | 5 | Amgen Inc. ($17.72) |
All Payment Transactions
152 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: ONCOLOGY | ||||||
| 12/30/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $29.83 | General |
| Category: Oncology | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Oncology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $28.01 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $22.99 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.60 | General |
| 11/07/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | PFIZER INC. | TALZENNA (Drug), XTANDI | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $27.21 | General |
| Category: Oncology | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.16 | General |
| Category: Oncology | ||||||
| 10/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.58 | General |
| Category: Oncology | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.42 | General |
| Category: Oncology | ||||||
| 10/04/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 09/11/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Oncology | ||||||
| 09/09/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $25.66 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $17.75 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: Oncology | ||||||
| 08/19/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $15.96 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 42 | 1,971 | 98,468 | $3.0M | $1.2M |
| 2022 | 46 | 2,162 | 94,615 | $3.1M | $1.3M |
| 2021 | 38 | 1,788 | 56,200 | $1.9M | $823,795 |
| 2020 | 37 | 1,858 | 52,276 | $1.9M | $805,779 |
Total Patients
7,779
Total Services
301,559
Medicare Billing
$4.1M
Procedure Codes
163
All Medicare Procedures & Services
163 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 23 | 15,400 | $1.4M | $666,290 | 47.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 45 | 7,200 | $180,000 | $133,022 | 73.9% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 12 | 2,730 | $259,350 | $97,460 | 37.6% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 61 | 9,430 | $226,320 | $55,403 | 24.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 297 | 533 | $106,600 | $48,200 | 45.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 105 | 258 | $70,950 | $34,624 | 48.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 90 | 303 | $119,685 | $30,020 | 25.1% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 93 | 57,120 | $114,240 | $22,667 | 19.8% |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 2023 | 12 | 216 | $151,200 | $20,753 | 13.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 161 | 229 | $34,350 | $15,430 | 44.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 80 | 196 | $26,460 | $12,052 | 45.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 70 | 71 | $28,400 | $9,572 | 33.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 112 | 157 | $23,550 | $7,674 | 32.6% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 14 | 21 | $17,325 | $7,447 | 43.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 62 | 62 | $18,910 | $7,362 | 38.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 48 | 79 | $15,800 | $7,308 | 46.3% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 15 | 306 | $32,130 | $5,419 | 16.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 150 | 424 | $23,320 | $4,510 | 19.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $9,750 | $4,027 | 41.3% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 13 | 22 | $7,700 | $3,974 | 51.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 70 | 241 | $12,050 | $2,805 | 23.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 27 | 57 | $10,260 | $2,622 | 25.6% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 17 | 26 | $5,200 | $1,826 | 35.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 30 | 85 | $8,075 | $1,766 | 21.9% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 15 | 32 | $5,280 | $1,346 | 25.5% |
About Dr. Angela Vanlandingham, M.D
Dr. Angela Vanlandingham, M.D is a Hematology & Oncology healthcare provider based in Mechanicsville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/26/2008. The National Provider Identifier (NPI) number assigned to this provider is 1538331939.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Angela Vanlandingham, M.D has received a total of $3,618 in payments from pharmaceutical and medical device companies, with $1,361 received in 2024. These payments were reported across 152 transactions from 51 companies. The most common payment nature is "Food and Beverage" ($2,916).
As a Medicare-enrolled provider, Vanlandingham has provided services to 7,779 Medicare beneficiaries, totaling 301,559 services with total Medicare billing of $4.1M. Data is available for 4 years (2020–2023), covering 163 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Mechanicsville, VA
- Active Since 03/26/2008
- Last Updated 01/20/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1538331939
Products in Payments
- Enhertu (Drug) $400.00
- OPDIVO (Biological) $177.97
- KEYTRUDA (Biological) $127.80
- SCEMBLIX (Drug) $118.49
- IMBRUVICA (Drug) $115.36
- ADCETRIS (Biological) $104.43
- XPOVIO (Drug) $99.42
- TAGRISSO (Drug) $86.49
- SARCLISA (Biological) $77.38
- Onivyde (Drug) $73.46
- OPDUALAG (Drug) $69.90
- Lenvima (Drug) $61.06
- JAKAFI (Drug) $59.38
- KRAZATI (Drug) $56.99
- Alecensa (Biological) $53.31
- KISQALI (Drug) $52.55
- IMFINZI (Biological) $48.95
- OJJAARA (Drug) $46.24
- RYBREVANT (Drug) $44.24
- XTANDI (Drug) $44.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Mechanicsville
Maura Hagan, M.d, M.D
Hematology & Oncology — Payments: $7,119
Hematology & Oncology $7,119
Dr. Aisha Zaidi, Md, MD
Hematology & Oncology — Payments: $3,983
Hematology & Oncology $3,983
Seaborn Wade, M.d, M.D
Hematology & Oncology — Payments: $3,820
Hematology & Oncology $3,820
Maurice Schwarz, M.d, M.D
Hematology & Oncology — Payments: $2,510
Hematology & Oncology $2,510